TAMPA, Fla., March 7, 2013 /PRNewswire/ -- ISPE announced today that it will hold its first-ever conference focused on benchmarking and advancing the development of Quality by Design (QbD) in the biopharmaceutical industry. The two-day event, taking place 10 – 11 April 2013 in San Francisco, Calif. USA, will feature workshops and discussions on the industry's progress since the introduction of A-Mab and steps for further adoption of QbD principles. The conference is endorsed by CASSS, a not-for-profit 501(c)(6) professional scientific society made up of over 4,000 industry, academic and public sector professionals.
"Quality by Design is a critical issue for the industry, with companies and global regulatory authorities working to help the industry adopt QbD practices," said Nancy Berg , ISPE President and CEO. "As the global pharmaceutical association representing the entire pharmaceutical lifecycle, ISPE will bring together top QbD experts to discuss how planning and controlling product evolution can lead to superior quality, better resource use and increased business effectiveness."
The State of Quality by Design in the Biopharmaceutical Industry Conference will offer in-depth case studies, lessons learned and best practices in implementing QbD. Pfizer's Roger Nosal , Vice President, Global Chemistry, Manufacturing and Controls (GCMC), will present a plenary address titled "Carpe Opportunite: Regulatory Experience with Implementation of QbD, An Industry Perspective." Mr. Nosal has an extensive history of leading advanced technology dialog among industry and regulators.
Speakers and delegates from Abbott, Amgen, Eli Lilly, Genentech, MedImmune, Merck, Pfizer, Roche and more will explore challenges and solutions with industr
Copyright©2012 PR Newswire.
All rights reserved